{"entity":{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","aka":[],"tldr":"Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer.","summary":"Jonathan Rosenberg led IMvigor210, the first pivotal study of a PD-L1 inhibitor in urothelial cancer, and EV-201, the trial that won enfortumab vedotin accelerated approval, and was a lead investigator of EV-103 and EV-302. He has also led erdafitinib and other FGFR3-directed studies. He chairs GU oncology at MSKCC and the Alliance GU committee.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenberg%20JE%5BAuthor%5D%20urothelial%20enfortumab"}],"tags":["urothelial","adc","immunotherapy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":["nectin4","pdl1"],"drugs":["enfortumab-vedotin","atezolizumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["ev-302"],"people":[],"bottlenecks":[],"keyPapers":["paper-ev-302-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Urothelial cancer","Antibody-drug conjugates","FGFR-targeted therapy","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenberg%20JE%5BAuthor%5D%20urothelial%20enfortumab"}],"papers":[{"title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy (EV-201)","journal":"JCO","year":2019,"doi":"10.1200/JCO.19.01140"},{"title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy (IMvigor210)","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(16)00561-4"},{"title":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312117","doi":"10.1056/NEJMoa2312117"}],"orcid":"0000-0003-2637-4249"},"route":"/people/jonathan-rosenberg/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/"}],"paper":[{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/"}]}}